7.3.1 Combined hormonal contraceptives (CHC)

See Contraception Guidance for advice on

  • Missed pill
  • Risk factors
  • Counselling advice
  • Drug interactions
  • Practical advice
  • Emergency contraception

In the absence of any other clinical reason, the product of lower acquisition cost should be chosen.

Evidence suggests that CHCs containing the 'third generation' progestogens gestodene or desogestrel are associated with an increased risk of venous thromboembolism (VTE) when compared with those containing the 'second generation' progestogens levonorgestrel or norethisterone.

CHC containing a 3rd generation progestogen may be suitable for women who experience unacceptable side-effects from other progestogens. It is important that the woman is aware of the possible increased risk of venous thromboembolism, backed up with an up-to-date leaflet. The Family Planning Association produce a suitable leaflet (The Combined Pill).

Monophasic low strength (21 day)

Gedarel® 20/150

(Ethinylestradiol with desogestrel)

  • Tablets 20 micrograms/150 micrograms (£1.69)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Millinette® 20/75

(Ethinylestradiol with gestodene)

  • Tablets 20 micrograms/75 micrograms (£1.80)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)

Monophasic standard strength (21 day)

Levest®

(Ethinylestradiol with levonorgestrel)

  • Tablets 30 micrograms/150 micrograms (£0.60)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Rigevidon®

(Ethinylestradiol with levonorgestrel)

  • Tablets 30 micrograms/150 micrograms (£0.63)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Brevinor®

(Ethinylestradiol with norethisterone)

  • Tablets 35 micrograms/500 micrograms (£0.66)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Millinette® 30/75

(Ethinylestradiol with gestodene)

  • Tablets 30 micrograms/75 micrograms (£1.37)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Gedarel® 30/150

(Ethinylestradiol with desogestrel)

  • Tablets 30 micrograms/150 micrograms (£1.40)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Cilique® 250/35

(Ethinylestradiol with norgestimate)

  • Tablets 35 micrograms/250 micrograms (£1.55)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Lizinna®

(Ethinylestradiol with norgestimate)

  • Tablets 35 micrograms/250 micrograms (£1.55)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)
Marvelon®

(Ethinylestradiol with desogestrel)

  • Tablets 30 micrograms/150 micrograms (£2.37)

Notes

  1. Prescribe by brand (to aid identification where products contain multiple ingredients, or to prevent confusion where multiple brands contain similar ingredients)

 

Home > Formulary > Chapters > 7. Obstetrics, gynaecology, and urinary-tract disorders > 7.3 Contraceptives > 7.3.1 Combined hormonal contraceptives (CHC)

 

  • First line
  • Second line
  • Specialist
  • Hospital